Dr. Soumerai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114Phone+1 617-724-4000- Is this information wrong?
Summary
- Dr. Jacob Soumerai is an oncologist in Boston, MA and is affiliated with Massachusetts General Hospital. He received his medical degree from Tufts University School of Medicine and has been in practice at the MGH Cancer Center since 2017. He specializes in hematologic oncology and is experienced in chronic lymphoid leukemia and lymphoma.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Massachusetts General HospitalResidency, Internal Medicine, 2011 - 2014
Tufts University School of MedicineClass of 2011
Certifications & Licensure
MA State Medical License 2013 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society, 2011
Clinical Trials
- Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma Start of enrollment: 2019 Sep 01
- Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL Start of enrollment: 2020 Oct 19
- Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL Start of enrollment: 2020 Dec 15
- Join now to see all
Publications & Presentations
PubMed
- Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.Catherine S Diefenbach, Thomas A Jandl, William Novotny, Jane Huang, Lu Miao, Prabhu Rajagopalan, Richard G Ghalie, Jacob D Soumerai, Deepa Jagadeesh, Adam Asch, Abhij...> ;British Journal of Haematology. 2024 Mar 19
- Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP.Nemec, R., Scherrer-Crosbie, M., Abramson, J., Redd, R., Gilman, H., Ho, T., Wu, J., Heemelaar, J., Neuberg, D., Hochberg, E., Barnes, J., Armand, P., Jacobsen, E., Ja...> ;Leukemia & Lymphoma. 2024 Feb 21
- 1 citationsReal-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.Lei, M., Sorial, M., Lou, U., Yu, M., Medrano, A., Ford, J., Nemec, R., Abramson, J., Soumerai, J.> ;Leukemia & Lymphoma. 2024 Jan 31
- Join now to see all
Abstracts/Posters
- Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisoc...Jacob D. Soumerai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Time to Second Treatment As a Proxy for Overall Survival in CLL/SLL: Identifying Risk Factors to Help Guide Treatment SelectionJacob D. Soumerai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R...Jacob D. Soumerai, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
ASH 2022: MCL Trials Break New Ground, May Change PracticeJanuary 30th, 2023- ‘Highly Encouraging’ MRD Results for Zanubrutinib Add-on in CLLJanuary 12th, 2022
- Clinical Challenges: Using MRD in Chronic Lymphocytic Leukemia ManagementDecember 22nd, 2021
- Join now to see all
Professional Memberships
- Fellow
Hospital Affiliations
Massachusetts General HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
